home / stock / tryp:cc / tryp:cc news

TRYP:CC News and Press, Tryp Therapeutics Inc. From 03/05/24

Stock Information
Company Name: Tryp Therapeutics Inc.
Stock Symbol: TRYP:CC
Market: CNQC
Website: tryptherapeutics.com
Menu
TRYP:CC TRYP:CC Quote TRYP:CC Short TRYP:CC News TRYP:CC Articles TRYP:CC Message Board
Get TRYP:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
TRYP:CC - Canadian Investment Regulatory Organization Trade Resumption - TRYP

Canadian Investment Regulatory Organization Trade Resumption - TRYP Canada NewsWire VANCOUVER, BC , March 5, 2024 /CNW/ - Trading resumes in: Company: Tryp Therpeutics Inc. CSE Symbol: TRYP All Issues: Yes Resumption (ET): 2:15 PM ...
TRYP:CC - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Interim Order from BC Supreme Court, Plans Meeting of Securityholders

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has obtained an interim order of the Supreme Court of British Colum...

TRYP:CC - Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting

KELOWNA, BC / ACCESSWIRE / February 8, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP)(OTCQB:TRYPF ), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet m...

TRYP:CC - Canadian Investment Regulatory Organization Trading Halt - TRYP

Canadian Investment Regulatory Organization Trading Halt - TRYP Canada NewsWire VANCOUVER, BC , Feb. 5, 2024 /CNW/ - The following issues have been halted by CIRO: Company: Tryp Therpeutics Inc. CSE Symbol: TRYP All Issues: Yes Reason: Cease Trade Ord...
TRYP:CC - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), Exopharm Limited Secure Approval from ASX for 'Pivotal' Two-Cent Waiver

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, announced that it has been granted a pivotal two-cent waiver by the...

TRYP:CC - Tryp Therapeutics and Exopharm Limited Secure Pivotal 2 Cent Waiver From ASX

KELOWNA, BC / ACCESSWIRE / January 26, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP )( OTCQB:TRYPF ), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet...

TRYP:CC - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) TRP-8803 Clinical Trial Reaches 'Significant Milestone'

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has received approval from Australia’s Human Research Ethics...
TRYP:CC - Tryp Therapeutics Announces Significant Milestone in Its Clinical Trial Program for Trp-8803 (IV-infused Psilocin)

KELOWNA BC / ACCESSWIRE / January 8, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP )( OTCQB:TRYPF ), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet m...

TRYP:CC - Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan

KELOWNA, BC / ACCESSWIRE / January 4, 2024 / Tryp Therapeutics Inc. (" Tryp " or the " Company ") ( CSE:TRYP ), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs,is pleased to...

TRYP:CC - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Inks Definitive Agreement with Exopharm Limited

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has signed a definitive agreement with Exopharm Limited ACN 163 765 991. The a...
Previous 10 Next 10